Lido Advisors LLC Purchases 9,444 Shares of Zoetis Inc. $ZTS

Lido Advisors LLC boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 33.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 37,889 shares of the company’s stock after buying an additional 9,444 shares during the period. Lido Advisors LLC’s holdings in Zoetis were worth $5,909,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in shares of Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after purchasing an additional 2,978 shares in the last quarter. Jupiter Asset Management Ltd. bought a new position in Zoetis during the first quarter valued at $2,278,000. PNC Financial Services Group Inc. grew its stake in shares of Zoetis by 3.9% in the 1st quarter. PNC Financial Services Group Inc. now owns 275,167 shares of the company’s stock worth $45,306,000 after buying an additional 10,294 shares in the last quarter. Cheviot Value Management LLC bought a new stake in shares of Zoetis in the 1st quarter worth about $119,000. Finally, Heritage Trust Co raised its position in shares of Zoetis by 32.6% during the 1st quarter. Heritage Trust Co now owns 5,953 shares of the company’s stock valued at $980,000 after buying an additional 1,463 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 0.7%

Shares of ZTS opened at $127.31 on Tuesday. The firm has a market capitalization of $56.11 billion, a price-to-earnings ratio of 21.91, a PEG ratio of 2.31 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $181.85. The company has a 50-day moving average of $135.42 and a 200 day moving average of $148.74.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same period last year, the company posted $1.58 earnings per share. The company’s quarterly revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.6%. Zoetis’s payout ratio is presently 33.67%.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Morgan Stanley reduced their price objective on Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a research note on Monday, November 10th. Argus reaffirmed a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. KeyCorp initiated coverage on shares of Zoetis in a research report on Thursday, November 20th. They set a “sector weight” rating on the stock. Stifel Nicolaus reduced their target price on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research note on Tuesday, November 18th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Six research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $178.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.